Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1,578,482 adults diagnosed during 2000–2014 in 59 countries (CONCORD-3)*

Veronica Di Carlo,1 Charles A. Stiller,2 Nora Eisemann,3 Andrea Bordoni,4 Melissa Matz,1 Maria P. Curado,5 Laetitia Daubisse-Marliac,6 Mikhail Valkov,7 Jean-Luc Bulliard,8,9 David Morrison,10 Chris Johnson,11 Fabio Girardi,1,12,13 Rafael Marcos-Gragera,14,15,16 Mario Sekerija,17 Siri Lærenningen,18 Eunice Sirri,19 Michel P. Coleman,1,12 Claudia Allemani1 and the CONCORD Working Group

1Cancer Survival Group, London School of Hygiene and Tropical Medicine, Keppel Street WC1E 7HT, London, UK
2National Disease Registration Service, NHS Digital, London, UK
3Institute of Social Medicine and Epidemiology, University of Lübeck, Ratzeburger Allee 160 23538, Lübeck, Germany
4Ticino Cancer Registry, Dipartimento Sanità e Socialità, Divisione della Salute Pubblica, Via Ciseri 10 6600, Locarno, Switzerland
5Goiânia Cancer Registry, Group of Epidemiology and Statistics on Cancer, AC Camargo Cancer Center, Rua Tamandaré 753 – Liberdade, SP, 01525-001, São Paulo, Brazil
6Tarn Cancer Registry, Institut Universitaire du Cancer Toulouse – OncoPole Institut C. Raguèd, 1 Avenue Irène Joliot-Curie 31059, Toulouse, France
7Northern State Medical University, Prospekt Triotisky 51 163000, Arkhangelsk, Russian Federation
8Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland
9Neuchâtel and Jura Tumour Registry, Neuchâtel, Switzerland
10Scottish Cancer Registry, Gyle Square, 1 South Gyle Crescent EH12 9EB, Edinburgh, UK
11Cancer Data Registry of Idaho, 615 North 7th Street, ID, 83701-1278, Boise, USA
12Cancer Division, University College London Hospitals NHS Foundation Trust, Euston Road WC1H 8NJ, London, UK
13Division of Medical Oncology 2, Veneto Institute of Oncology IVO-RHCCS, ViaGattamelata 64 35128, Padova, Italy
14Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology (ICO), IDIBGI, Oncology Coordination Plan, Department of Health Government of Catalonia, 17004, Girona, Spain
15University of Girona (UdG), 17004, Girona, Spain
16CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain
17Croatian National Cancer Registry, Croatian Institute of Public Health, Rockefeller Street 7 10000, Zagreb, Croatia
18Cancer Registry of Norway, Ullernchausseen 64 0379, Oslo, Norway
19Epidemiological Cancer Registry of Lower Saxony, Offiss Caree GmbH, Industriestr 92 6121, Oldenburg, Germany

Linked Comment: C.M. Olsen. Br J Dermatol 2022; 187:284.

Abstract

Background CONCORD-3 highlighted wide disparities in population-based 5-year net survival for cutaneous melanoma during 2000–2014. Clinical evidence suggests marked international differences in the proportion of lethal acral and nodular subtypes of cutaneous melanoma.

Objectives We aimed to assess whether the differences in morphology may explain global variation in survival.

Methods Patients with melanoma were grouped into the following seven morphological categories: malignant melanoma, not otherwise specified (International Classification of Diseases for Oncology, third revision morphology code 8720), superficial spreading melanoma (8743), lentigo maligna melanoma (8742), nodular melanoma (8721), acral lentiginous melanoma (8744), desmoplastic melanoma (8745) and other morphologies (8722–8723, 8726–8727, 8730, 8740–8741, 8746, 8761, 8770–8774, 8780). We estimated net survival using the nonparametric Pohar Perme estimator, correcting for background mortality.
by single year of age, sex and calendar year in each country or region. All-ages survival estimates were standardized using the International Cancer Survival Standard weights. We fitted a flexible parametric model to estimate the effect of morphology on the hazard of death.

Results Worldwide, the proportion of nodular melanoma ranged between 7% and 13%. Acral lentiginous melanoma accounted for less than 2% of all registrations but was more common in Asia (6%) and Central and South America (7%). Overall, 36% of tumours were classified as superficial spreading melanoma. During 2010–2014, age-standardized 5-year net survival for superficial spreading melanoma was 95% or higher in Oceania, North America and most European countries, but was only 71% in Taiwan. Survival for acral lentiginous melanoma ranged between 66% and 95%. Nodular melanoma had the poorest prognosis in all countries. The multivariable analysis of data from registries with complete information on stage and morphology found that sex, age and stage at diagnosis only partially explain the higher risk of death for nodular and acral lentiginous subtypes.

Conclusions This study provides the broadest picture of distribution and population-based survival trends for the main morphological subtypes of cutaneous melanoma in 59 countries. The poorer prognosis for nodular and acral lentiginous melanomas, more frequent in Asia and Latin America, suggests the need for health policies aimed at specific populations to improve awareness, early diagnosis and access to treatment.

What is already known about this topic?
- The histopathological features of cutaneous melanoma vary markedly worldwide.
- The proportion of melanomas with the more aggressive acral lentiginous or nodular histological subtypes is higher in populations with predominantly dark skin than in populations with predominantly fair skin.

What does this study add?
- We aimed to assess the extent to which these differences in morphology may explain international variation in survival when all histological subtypes are combined.
- This study provides, for the first time, international comparisons of population-based survival at 5 years for the main histological subtypes of melanoma for over 1.5 million adults diagnosed during 2000–2014.
- This study highlights the less favourable distribution of histological subtypes in Asia and Central and South America, and the poorer prognosis for nodular and acral lentiginous melanomas.
- We found that later stage at diagnosis does not fully explain the higher excess risk of death for nodular and acral lentiginous melanoma compared with superficial spreading melanoma.

The incidence of cutaneous melanoma has been rising steadily in most white populations over the past 50 years. It is now one of the 10 most common malignancies in Oceania, North America and Europe, with age-standardized incidence rates in the range of 7.0–36.6 per 100 000 person-years. By contrast, melanoma is rare in populations of Asian and African origin, where incidence rates are in the range of 0.4–3.0 per 100 000 person-years. The histopathological features of cutaneous melanoma vary markedly worldwide. The proportion of melanomas with the more aggressive acral lentiginous or nodular histological subtypes is higher in populations with predominantly dark skin than in populations with predominantly fair skin.

The third cycle of the CONCORD programme for the global surveillance of cancer survival (CONCORD-3) highlighted wide disparities in 5-year net survival from cutaneous melanoma, which was lower in Asian populations than in the rest of the world. Age-standardized 5-year net survival for adults
(15–99 years) diagnosed during the period 2010–2014 was 90% or higher in the USA, Australia, New Zealand and most Nordic countries, but was 60% or lower in Ecuador, China, Korea, Singapore and Taiwan.

Stage at diagnosis is recognized as the most important predictor of survival.\(^7\)–\(^10\) Age at diagnosis is also a prognostic factor, and several studies have shown much higher survival for younger patients.\(^11\)–\(^15\) However, the prognostic role of morphology in cutaneous melanoma is controversial. Traditionally, melanomas of the skin have been classified into the following three fairly well-defined subgroups, characterized by different patterns of growth: superficial spreading and lentigo maligna melanoma, which is characterized by a long period of superficial growth; nodular melanoma, which is more likely to penetrate into the deeper layers of the skin if not removed; and acral lentiginous melanoma, which mostly develops on the extremities but displays similar biological behaviour to that of nodular melanoma.\(^16\)

Despite the advent of high-resolution genomics and other proposed approaches for the classification of melanocytic tumours, the diagnosis of the different subtypes should continue to be based on the pathologist’s interpretation of the histology and how it fits into the World Health Organization (WHO) Classification of Tumours, commonly known as the WHO ‘Blue Books’.\(^17\) However, the morphological classification has not been considered useful for prognostic purposes because of the commonly held view that the clinical development of all melanomas is similar, whatever the histological subtype, spreading horizontally within the epidermis and then extending vertically into the dermis, and that they converge in their biological behaviour once they metastasize.\(^18\)

In this study, we aimed to describe the histological distribution of cutaneous melanoma for adults diagnosed during 2000–2014 in the 59 countries that contributed data to CONCORD-3 and to produce the first international comparison of trends in population-based age-standardized 5-year net survival by morphological subtype. We also aimed to examine the role of morphological subtype in the prognosis of cutaneous melanoma.

Materials and methods

Anonymized individual tumour registrations for patients diagnosed during 2000–2014 with one of 18 cancers or groups of malignancies, including melanoma, were provided for CONCORD-3 by 322 population-based cancer registries in 71 countries worldwide (full details of the CONCORD Working Group are provided in Appendix S1; see Supporting Information). Patients were followed up for their vital status up to 31 December 2014. Data acquisition, ethical approval and data quality control have been described elsewhere.\(^6\)

We asked participating registries to submit all registrations for malignant melanoma, regardless of anatomical site. Melanoma was defined by morphology codes in the range 8720–8790 according to the International Classification of Diseases for Oncology, third revision (ICD-O-3).\(^19\) We focused this analysis of survival on melanomas arising in the skin (ICD-O-3 topography C44.0–C44.9, including the skin of the labia majora (C51.0), vulva (C51.9), penis (C60.9) and scrotum (C63.2). Survival from melanomas arising in internal organs and in the eye will be examined in a subsequent analysis. To facilitate quality control and comparison of the intensity of early diagnostic and screening activity, we requested all melanoma registrations, regardless of behaviour, whether benign (behaviour code 0), uncertain (behaviour code 1), in situ (behaviour code 2) or invasive (behaviour code 3). However, survival analyses included only primary invasive melanomas.

Records with incomplete data, or of tumours that were benign, in situ, of uncertain behaviour, metastatic from another organ, or unknown if primary or metastatic, or for patients aged outside the range 15–99 years, were not included in survival analyses. We excluded tumours registered only on the basis of a death certificate or discovered at autopsy, as the survival is unknown in these cases. We also excluded records for which sex or vital status was unknown, and records with an invalid date or sequence of dates were also omitted.

Patients were grouped according to the following seven morphological categories using the ICD-O-3 classification: malignant melanoma, not otherwise specified (NOS) (morphology code 8720), superficial spreading melanoma (8743), lentigo maligna melanoma (8742), nodular melanoma (8721), acral lentiginous melanoma (8744), desmoplastic melanoma (8745) and other morphologies (8722–8723, 8726–8727, 8730, 8740–8741, 8746, 8761, 8770–8774, 8780).

Patients were grouped according to calendar period of diagnosis, i.e. 2000–2004, 2005–2009 or 2010–2014. We examined time trends in the morphology distribution for each country. We also estimated trends in age-standardized 5-year net survival by country and morphology with the nonparametric Pohar Perme estimator,\(^20\) using the STATA (StataCorp, College Station, TX, USA) command stns.\(^21\) The cohort approach was used for patients diagnosed during the periods 2000–2004 and 2005–2009 because these patients had all been followed up for at least 5 years. We used the period approach\(^22\) to estimate survival for patients diagnosed during 2010–2014 because 5-year follow-up for vital status was not available for all patients up to 31 December 2014.

To control for wide differences in background mortality based on geographical area, sex, and over time, we constructed life tables of all-cause mortality in the general population for each country or registry by single year of age, sex, calendar year and, where possible, by race/ethnicity (Israel, Singapore, USA, Australian Northern Territory and New Zealand).

We estimated 5-year net survival by morphology in each of five age groups (15–44 years, 45–54 years, 55–64 years, 65–74 years and 75–99 years). We obtained age-standardized estimates for all age groups combined using the International Cancer Survival Standard type 2 weights for the five age groups (0.28, 0.17, 0.21, 0.20 and 0.14).\(^23\) We did not estimate survival if fewer than 10 patients were available for analysis in a given combination of morphological subtype and calendar period. If 10–49 patients were available for a given
calendar period, we only estimated survival for all ages combined. If 50 or more patients were diagnosed during the periods 2000–2004 and 2005–2009, we attempted survival estimation for each age group in each calendar period. For 2010–2014, we estimated net survival using the period approach, including in the analyses all patients diagnosed during the 5-year period from 2010 to 2014, plus those diagnosed before 2010 who were still alive at the beginning of 2010. Therefore, for the period 2010–2014 the threshold of 50 or more patients required to attempt age-standardization applies to the combined cohort of patients. If a single age-specific estimate could not be obtained, we merged the data for adjacent age groups and assigned the combined estimate to both age groups before standardization for age. If two or more age-specific estimates could not be obtained, we reported only the unstandardized estimate for all ages combined. The pooled estimates for countries with more than one registry do not include data from registries for which the estimates were less reliable. Less reliable estimates are shown with a footnote in Tables 1–3 when such estimates were the only available information from a given country or territory (see footnote in Tables 1–3 for the definition of less reliable estimates). Here, we comment only on reliable, age-standardized survival estimates. Continental regions were defined using the United Nations Geoscheme.24

To estimate the effect of morphology on the hazard of death owing to melanoma, we fitted a flexible parametric model on the log cumulative hazard scale, using stpm225 in STATA. We restricted this analysis to registries where at least 65% of registrations had a specific morphology code, i.e. not malignant melanoma, NOS. Among these registries, we further selected those for which data on stage were available for at least 75% of registrations using one of the following classifications: Union for International Control Tumour–Node–Metastasis staging system, 7th edition,26 Condensed TNM27 or Surveillance Epidemiology and End Results Summary Stage 2000.28 Using this constraint, we were able to include data from one regional cancer registry in Germany (Lower Saxony), two registries in Spain (Basque Country and Granada) and the Norwegian national cancer registry.

For each country, we first fitted a model with only morphology as a covariate (model 1). We then included, as additional covariables, sex, a restricted cubic spline for the effect of age at diagnosis (four degrees of freedom) and stage at diagnosis (metastatic vs. nonmetastatic) (model 2). We excluded patients for whom stage at diagnosis was unknown (complete case analysis).

Results

We obtained data from 284 registries in 59 countries for 2 303 095 adults who were diagnosed with melanoma during 2000–2014 (Table 4). Of these patients, 49% were diagnosed in North America, 37% in Europe, 12% in Oceania, and only 2% in Asia and less than 1% in both Africa and in Central and South America.

A total of 637 957 patients (28%) who were diagnosed with an in situ tumour were excluded from survival analysis, which ranged from 11% in Central and South America to 35% in North America. The proportion of in situ melanoma was 20% or higher in 10 countries (Table 4), which suggests that the approach to early diagnosis in these countries was highly effective. We excluded a further 78 587 patients for other reasons (see footnote in Table 4). The proportion of melanomas of benign or uncertain behaviour was particularly high in Norway (22%), highlighting the intensive monitoring activity for atypical naevi and premalignant lesions in this country.

Of the 1 586 551 eligible patients, we further excluded 7139 patients (0.5%) who were diagnosed only on the basis of a death certificate or where melanoma was discovered at autopsy, and 930 patients (less than 0.1%) were excluded for other reasons. Finally, 1 578 482 patients diagnosed with a primary invasive melanoma of the skin were available for survival analysis (99.5% of those eligible). More than 99% of these tumours were microscopically confirmed, either cytologically or histologically.

About 42% of the tumours were registered as malignant melanoma, NOS. The proportion of such tumours was generally high in countries in Asia (76%), Central and South America (63%), North America (51%) and Africa (46%) and much lower in Oceania (33%). In Europe, the proportion of melanomas with a nonspecific morphology was higher in Eastern European countries (57%) than in Southern (37%), Northern (32%) and Western European countries (27%). The proportion of melanomas diagnosed with a nonspecific morphology fell substantially in Australia (from 40% in 2000–2004 to 26% in 2010–2014), Denmark (from 42% to 11%), Iceland (from 36% to 18%), Italy (from 32% to 19%), Lithuania (from 85% to 35%), Portugal (from 70% to 35%) and the UK (from 39% to 23%) (Table S1; see Supporting Information).

Overall, superficial spreading melanoma was the second most common histological subtype (36% of all cases). It accounted for more than half of the patients in Denmark, France, Iceland, the Netherlands, Norway, Sweden and Switzerland (Figure 1). Nodular melanoma accounted for 7% of all cases in North America and Asia, 9% in Oceania and 13% in Central and South America. In Europe, 12% of the cases were registered as nodular melanoma, with higher proportions in the Czech Republic, Ireland, Norway, Romania, Slovakia and Sweden. About 6% of adults were diagnosed with lentigo maligna melanoma, ranging from 2% in Asia to 8% in Oceania. Acral lentiginous melanoma was very rare in North America, Europe and Oceania (less than 2% of all cases) but the proportion was higher in Central and South America (more than 10% in Colombia, Costa Rica, Guadeloupe and Martinique) and Asia (more than 10% in Korea, Singapore and Taiwan). Less than 1% of the patients were diagnosed with desmoplastic melanoma. The proportion of patients diagnosed with other morphological subtypes was higher than 20% in Estonia, Italy and Latvia.
| Country | Year | N | NS (%) | 95% CI | Year | N | NS (%) | 95% CI | Year | N | NS (%) | 95% CI | Year | N | NS (%) | 95% CI | Year | N | NS (%) | 95% CI | Year | N | NS (%) | 95% CI | Year | N | NS (%) | 95% CI |
|---------|------|---|-------|-------|------|---|-------|-------|------|---|-------|-------|------|---|-------|-------|------|---|-------|-------|------|---|-------|-------|------|---|-------|-------|
| Argentina | 2000-2004 | 30 | 71.2 | 50.7-91.7 | 2000-2004 | 11 | 95.5 | 92.3-98.7 | 2000-2004 | 24 | 90.0 | 85.9-94.0 |
| | 2005-2009 | 19 | 71.5 | 61.8-81.7 | 2005-2009 | 41 | 84.4 | 65.0-100.0 | 2005-2009 | 21 | 95.5 | 72.2-100.0 |
| | 2010-2014 | 2014-2014 | 43 | 85.0 | 68.9-100.0 | 2014-2014 | 52 | 95.3 | 72.8-100.0 |
| Brazil | 2000-2004 | 30 | 71.2 | 50.7-91.7 | 2000-2004 | 11 | 95.5 | 92.3-98.7 | 2000-2004 | 24 | 90.0 | 85.9-94.0 |
| | 2005-2009 | 19 | 71.5 | 61.8-81.7 | 2005-2009 | 41 | 84.4 | 65.0-100.0 | 2005-2009 | 21 | 95.5 | 72.2-100.0 |
| | 2010-2014 | 2014-2014 | 43 | 85.0 | 68.9-100.0 | 2014-2014 | 52 | 95.3 | 72.8-100.0 |
| | 2000-2004 | 30 | 71.2 | 50.7-91.7 | 2000-2004 | 11 | 95.5 | 92.3-98.7 | 2000-2004 | 24 | 90.0 | 85.9-94.0 |
| | 2005-2009 | 19 | 71.5 | 61.8-81.7 | 2005-2009 | 41 | 84.4 | 65.0-100.0 | 2005-2009 | 21 | 95.5 | 72.2-100.0 |
| | 2010-2014 | 2014-2014 | 43 | 85.0 | 68.9-100.0 | 2014-2014 | 52 | 95.3 | 72.8-100.0 |
| | 2000-2004 | 30 | 71.2 | 50.7-91.7 | 2000-2004 | 11 | 95.5 | 92.3-98.7 | 2000-2004 | 24 | 90.0 | 85.9-94.0 |
| | 2005-2009 | 19 | 71.5 | 61.8-81.7 | 2005-2009 | 41 | 84.4 | 65.0-100.0 | 2005-2009 | 21 | 95.5 | 72.2-100.0 |
| | 2010-2014 | 2014-2014 | 43 | 85.0 | 68.9-100.0 | 2014-2014 | 52 | 95.3 | 72.8-100.0 |
| | 2000-2004 | 30 | 71.2 | 50.7-91.7 | 2000-2004 | 11 | 95.5 | 92.3-98.7 | 2000-2004 | 24 | 90.0 | 85.9-94.0 |
| | 2005-2009 | 19 | 71.5 | 61.8-81.7 | 2005-2009 | 41 | 84.4 | 65.0-100.0 | 2005-2009 | 21 | 95.5 | 72.2-100.0 |
| | 2010-2014 | 2014-2014 | 43 | 85.0 | 68.9-100.0 | 2014-2014 | 52 | 95.3 | 72.8-100.0 |

NOS, not otherwise specified. *Data with 100% coverage of the national population. **Survival estimate considered less reliable, because 15% or more of patients were (i) lost to follow-up or censored alive within 5 years of diagnosis (or if diagnosed in 2010 or later, before 31 December 2014), or (ii) registered only from a death certificate or at autopsy, or (iii) registered with incomplete dates, i.e. unknown year of birth, unknown month and/or year of diagnosis or unknown year of vital status. Italicize denote survival estimates that are not age-standardized. Bold values denote age-standardized survival estimates.
## NOS, not otherwise specified.

### Table 2 Number of patients and age-standardized 5-year net survival (NS,%) with 95% confidence interval (CI): adults (15–99 years) diagnosed with melanoma of the skin in Asia and Oceania, by continent, country, morphology and calendar period of diagnosis (2000–2004, 2005–2009, 2010–2014)

| Country | Morphology | Year | N | NS (%) | 95% CI | Year | N | NS (%) | 95% CI | Year | N | NS (%) | 95% CI |
|---------|------------|------|---|--------|--------|------|---|--------|--------|------|---|--------|--------|
| **Asia** |            |      |   |        |        |      |   |        |        |      |   |        |        |
| China   | Superficial spreading melanoma | 2000-2004 | 74 | 96.2 | 88.9–100.0 | 2009-2010 | 59 | 73.8 | 62.8–84.7 | 2014-2015 | 110 | 70.3 | 50.3–89.8 | 110 | 70.3 | 50.3–89.8 |
|         | Lentigo maligna melanoma |      | 538 | 44.7 | 39.8–49.5 | 623 | 48.4 | 43.3–53.6 | 15 | 61.2 | 51.7–71.1 | 17 | 69.9 | 41.1–98.7 |
| China   | Nodular melanoma |      | 2009-2010 | 101 | 87.3 | 78.8–95.8 | 2014-2015 | 94 | 71.4 | 59.9–82.9 | 15 | 61.2 | 51.7–71.1 | 17 | 69.9 | 41.1–98.7 |
|         | Acral lentiginous melanoma |      | 2009-2010 | 2009-2010 | 143 | 97.1 | 92.1–100.0 | 2014-2015 | 22 | 66.6 | 41.0–92.2 | 15 | 61.2 | 51.7–71.1 | 17 | 69.9 | 41.1–98.7 |
| China   | Desmoplastic melanoma |      | 2009-2010 | 316 | 68.9 | 62.5–75.3 | 2014-2015 | 23 | 80.8 | 51.6–100.0 | 15 | 61.2 | 51.7–71.1 | 17 | 69.9 | 41.1–98.7 |
|         | Malignant melanoma, NOS |      | 2009-2010 | 2009-2010 | 74 | 98.7 | 93.6–100.0 | 2014-2015 | 26 | 79.3 | 56.6–100.0 | 11 | 51.0 | 20.7–81.2 | 15 | 61.2 | 51.7–71.1 |
|         | Other melanoma morphologies |      | 2009-2010 | 2009-2010 | 355 | 97.7 | 93.8–100.0 | 2014-2015 | 3114 | 87.8 | 86.3–89.6 | 64 | 64.6 | 52.9–76.2 | 15 | 61.2 | 51.7–71.1 |

© 2022 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
| Year | Country | Sample Size | Mean Age | Standard Deviation | Median Age | Percent Male | Percent Female |
|------|---------|-------------|----------|--------------------|------------|--------------|---------------|
| 2004 | United States | 5000 | 55.2 | 15.7 | 50.0 | 48.7 | 51.3 |
| 2005 | United States | 5500 | 56.3 | 16.8 | 51.0 | 50.1 | 51.9 |
| 2006 | United States | 6000 | 57.4 | 17.9 | 52.1 | 51.2 | 52.8 |
| 2007 | United States | 6500 | 58.5 | 19.0 | 53.2 | 52.3 | 53.9 |
| 2008 | United States | 7000 | 59.6 | 20.1 | 54.3 | 53.4 | 55.0 |

(continued)
| Country | Year | % Alive | 95% CI | N | Age-standardized survival estimate | N | Rate (95% CI) | N | Mean follow-up years | % Alive | 95% CI |
|---------|------|---------|--------|----|-----------------------------------|----|----------------|----|---------------------|---------|--------|
| Norway  | 2000-2004 | 92.7 | 88.4-96.9 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2005 | 92.0 | 87.7-95.2 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2006-2010 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2011-2015 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2016-2020 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2021-2025 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2026-2030 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2031-2035 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2036-2040 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2041-2045 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2046-2050 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2051-2055 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2056-2060 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2061-2065 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2066-2070 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2071-2075 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2076-2080 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2081-2085 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2086-2090 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2091-2095 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2096-2010 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2011-2020 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2021-2030 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2031-2040 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2041-2050 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2051-2060 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2061-2070 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2071-2080 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2081-2090 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |
| Norway  | 2091-2010 | 93.2 | 90.7-95.4 | 27 | 63 | 87.9-92.2 | 27 | 63 | 46.1-63.6 | 81.6 | 78.2-83.6 |

Note: Standardized survival estimates.
### Table 4 Data quality indicators, patients diagnosed with melanoma of the skin during 2000–2014, by continent and country

| Calendar period | Patients submitted | Incomplete dates | In situ | Other | Eligible patients | DCO | Other | Available for analysis | MV | Nonspecific morphology | Lost to follow-up | Censored |
|-----------------|-------------------|------------------|--------|-------|-------------------|-----|--------|-----------------------|----|----------------------|------------------|----------|
| Africa          |                    |                  |        |       |                   |     |        |                       |    |                      |                  |          |
| Algerian registries | 2000–2014        | 331              | 13.3   | 0.0   | 0.9              | 284 |        | 0.0                  | 12.7 | 248                  | 100.0           | 47.6      |
| Mauritius        | 2010–2012         | 5                | 0.0    | 0.0   | 20.0             | 4   |        | 0.0                  | 4    | 100.0                | 100.0           | 0.0       |
| Nigeria (Ibadan) | 2005–2014         | 87               | 4.6    | 0.0   | 16.1             | 69  |        | 0.0                  | 4    | 97.2                 | 92.8            | 87.0      |
| South Africa (Eastern Cape) | 2000–2014 | 75               | 0.0    | 0.0   | 37.3             | 47  |        | 0.0                  | 47   | 76.6                 | 83.0            | 44.7      |
| America (Central and South) |          |                  |        |       |                   |     |        |                       |    |                      |                  |          |
| Argentinian registries | 2000–2013       | 1196             | 4.7    | 0.8   | 3.3              | 1092|        | 0.7                  | 0.0  | 1084                 | 99.6            | 67.7      |
| Brazilian registries | 2000–2014        | 2169             | 0.7    | 12.7  | 5.6              | 1758|        | 4.8                  | 0.0  | 1674                 | 99.2            | 73.1      |
| Chilian registries | 2000–2012        | 569              | 0.0    | 0.0   | 25.5             | 555 |        | 0.2                  | 0.0  | 554                  | 99.5            | 60.1      |
| Colombian registries | 2000–2014        | 1698             | 3.8    | 5.2   | 10.0             | 1376|        | 0.2                  | 0.0  | 1373                 | 98.8            | 49.4      |
| Costa Rica        | 2002–2014         | 1448             | 0.0    | 0.0   | 0.8              | 1436|        | 0.0                  | 0.0  | 1432                 | 98.3            | 44.7      |
| Ecuadorian registries | 2000–2013        | 1483             | 11.2   | 8.4   | 6.5              | 1096|        | 0.4                  | 1.1  | 1080                 | 98.8            | 78.0      |
| Guadeloupe (France) | 2008–2013        | 177              | 0.0    | 0.0   | 13.3             | 54  |        | 0.0                  | 0.0  | 54                   | 100.0           | 72.4      |
| Martinique (France) | 2000–2012        | 177              | 0.0    | 0.0   | 28.0             | 172 |        | 0.0                  | 4.7  | 164                  | 100.0           | 32.8      |
| Puerto Rico       | 2000–2011         | 1810             | 2.2    | 34.6  | 4.5              | 1062|        | 2.2                  | 0.0  | 1039                 | 99.3            | 75.6      |
| America (North)   |                    |                  |        |       |                   |     |        |                       |    |                      |                  |          |
| Canadian registries | 2000–2014        | 94 011           | 0.1    | 17.2  | 4.5              | 73 496|        | 0.3                  | 0.0  | 73 278               | 95.6            | 41.8      |
| US registries     | 2000–2014         | 1 040 814        | 0.6    | 35.2  | 2.6              | 632 861|       | 0.5                  | 0.0  | 629 816              | 100.0           | 52.0      |
| Asia             |                    |                  |        |       |                   |     |        |                       |    |                      |                  |          |
| Chinese registries | 2001–2013         | 1733             | 0.2    | 0.0   | 16.1             | 1450|        | 0.1                  | 0.0  | 1449                 | 99.0            | 95.4      |
| Cyprus           | 2004–2014         | 687              | 3.6    | 3.1   | 6.1              | 599 |        | 1.7                  | 0.0  | 589                  | 99.7            | 32.8      |
| Indian registries | 2000–2004         | 61               | 0.0    | 0.0   | 8.2              | 56  |        | 0.0                  | 7.1  | 52                   | 98.1            | 94.2      |
| Israel           | 2000–2013         | 18 303           | 0.0    | 28.3  | 4.2              | 12 348|       | 0.7                  | 0.0  | 12 265               | 98.0            | 78.1      |
| Japanese registries | 2000–2014        | 6462             | 1.3    | 10.4  | 22.3             | 42 632|       | 5.7                  | 0.0  | 40 198               | 95.3            | 88.1      |
| Jordan           | 2000–2004         | 306              | 0.3    | 1.0   | 27.8             | 217 |        | 0.0                  | 1.4  | 214                  | 99.5            | 84.1      |
| Korea            | 2000–2014         | 5824             | 0.9    | 0.0   | 0.0              | 5771|        | 0.0                  | 0.0  | 5771                 | 98.6            | 74.9      |
| Kuwait           | 2000–2003         | 21               | 0.0    | 0.0   | 14.3             | 18  |        | 0.0                  | 0.0  | 18                   | 100.0           | 72.2      |
| Qatar            | 2000–2014         | 61               | 0.0    | 1.6   | 8.2              | 55  |        | 0.0                  | 0.0  | 55                   | 98.2            | 87.3      |
| Singapore        | 2000–2004         | 521              | 0.0    | 9.0   | 20.3             | 368 |        | 0.3                  | 0.0  | 367                  | 100.0           | 56.1      |
| Taiwan           | 2000–2014         | 3123             | 0.3    | 3.4   | 0.6              | 2988|        | 0.0                  | 0.0  | 2988                 | 100.0           | 64.0      |
| Thai registries  | 2000–2014         | 817              | 0.0    | 0.0   | 5.9              | 769 |        | 0.0                  | 9.6  | 695                  | 99.7            | 95.0      |
| Turkish registries | 2000–2013        | 3799             | 1.4    | 4.8   | 18.4             | 2866|        | 0.3                  | 0.0  | 2856                 | 99.3            | 64.8      |
| Europe           |                    |                  |        |       |                   |     |        |                       |    |                      |                  |          |
| Austria          | 2000–2014         | 28 233           | 0.0    | 24.2  | 5.9              | 19 742|       | 2.9                  | 0.1  | 19 150               | 97.5            | 65.4      |
| Belgium          | 2004–2014         | 29 278           | 0.0    | 22.8  | 2.4              | 21 905|       | 0.0                  | 0.0  | 21 905               | 99.9            | 36.3      |
| Bulgaria         | 2000–2014         | 6057             | 0.0    | 0.0   | 0.0              | 6056|        | 3.0                  | 0.0  | 5875                 | 100.0           | 73.7      |

(continued)
Table 4 (continued)

| Calendar period | Eligible patients | DCO | Other | Available for analysis | MV | Non-specific morphology | Lost to follow-up | Censored |
|------------------|-------------------|------|-------|------------------------|----|------------------------|------------------|----------|
| Patients submitted | Incomplete dates | In situ | Other | | | | | |
| Croatia | 2000–2014 | 8602 | 0.0 | 2.0 | 3.5 | 8126 | 3.4 | 0.0 | 7848 | 99.9 | 90.4 | 0.0 | 0.0 |
| Czech Republic | 2000–2014 | 33 285 | 0.0 | 16.0 | 0.5 | 27 802 | 0.0 | 0.0 | 27 800 | 100.0 | 31.8 | 0.0 | 0.0 |
| Denmark | 2000–2014 | 24 683 | 0.0 | 0.0 | 0.2 | 24 630 | 0.0 | 0.0 | 24 630 | 99.7 | 21.6 | 0.6 | 0.0 |
| Estonia | 2000–2012 | 2556 | 0.0 | 11.8 | 9.9 | 2002 | 0.9 | 0.0 | 1983 | 98.4 | 31.1 | 1.2 | 0.0 |
| Finland | 2000–2014 | 15 873 | 0.4 | 0.0 | 5.3 | 14 968 | 0.1 | 0.0 | 14 949 | 100.0 | 90.8 | 0.3 | 0.0 |
| French registries | 2000–2010 | 14 962 | 0.3 | 0.0 | 6.0 | 14 017 | 0.1 | 0.0 | 13 677 | 100.0 | 11.4 | 3.4 | 0.0 |
| German registries | 2000–2014 | 99 363 | 0.3 | 16.2 | 2.6 | 80 338 | 2.0 | 0.0 | 78 713 | 99.4 | 28.4 | 0.6 | 28.7 |
| Gibraltar | 2000–2010 | 39 | 0.0 | 12.8 | 7.7 | 31 | 0.0 | 0.0 | 31 | 100.0 | 19.4 | 0.0 | 51.6 |
| Iceland | 2000–2014 | 715 | 0.0 | 0.0 | 0.3 | 713 | 0.0 | 0.0 | 713 | 99.9 | 29.3 | 0.0 | 0.0 |
| Ireland | 2000–2013 | 14 683 | 0.0 | 35.3 | 0.1 | 9475 | 0.1 | 0.0 | 9470 | 99.8 | 36.9 | 0.0 | 0.0 |
| Italian registries | 2000–2012 | 53 776 | 0.0 | 7.8 | 5.4 | 46 634 | 0.1 | 0.0 | 46 607 | 98.2 | 26.5 | 1.2 | 1.5 |
| Latvia | 2000–2014 | 2507 | 0.0 | 0.0 | 0.2 | 2503 | 0.1 | 0.0 | 2501 | 99.8 | 47.5 | 0.0 | 0.0 |
| Lithuania | 2000–2012 | 4129 | 0.0 | 6.3 | 13.4 | 3317 | 0.0 | 0.0 | 3317 | 100.0 | 55.8 | 0.0 | 0.9 |
| Malta | 2000–2013 | 725 | 0.0 | 14.2 | 10.9 | 543 | 0.4 | 0.0 | 541 | 99.6 | 36.4 | 0.0 | 0.0 |
| The Netherlands | 2000–2014 | 80 641 | 0.0 | 20.0 | 6.6 | 59 141 | 0.0 | 0.0 | 59 088 | 100.0 | 13.2 | 1.0 | 1.1 |
| Norway | 2000–2014 | 31 469 | 0.0 | 8.6 | 27.9 | 19 994 | 0.0 | 0.0 | 19 994 | 99.9 | 21.0 | 0.3 | 0.0 |
| Poland | 2000–2014 | 38 834 | 0.0 | 0.2 | 7.3 | 35 932 | 0.0 | 0.3 | 35 834 | 100.0 | 77.1 | 0.0 | 0.0 |
| Portugal | 2000–2010 | 10 897 | 0.0 | 3.9 | 11.5 | 9 051 | 0.0 | 0.0 | 9 051 | 99.9 | 77.1 | 0.0 | 0.0 |
| Romania (Cluj) | 2006–2012 | 515 | 0.0 | 3.9 | 11.5 | 436 | 0.0 | 0.0 | 436 | 98.9 | 50.9 | 0.0 | 0.0 |
| Russian registries | 2000–2014 | 50 000 | 0.0 | 11.5 | 436 | 36 786 | 0.0 | 0.0 | 36 786 | 99.9 | 77.1 | 0.0 | 0.0 |
| Slovakian | 2000–2010 | 7933 | 0.0 | 11.1 | 436 | 6478 | 1.4 | 0.0 | 6389 | 100.0 | 55.8 | 0.0 | 0.0 |
| Slovenia | 2000–2013 | 7442 | 0.0 | 18.8 | 3.5 | 5605 | 0.0 | 0.0 | 5603 | 99.7 | 36.3 | 0.0 | 0.0 |
| Spanish registries | 2000–2013 | 14 599 | 0.5 | 18.8 | 3.5 | 11 292 | 0.3 | 0.1 | 11 242 | 99.7 | 25.8 | 0.6 | 0.1 |
| Sweden | 2000–2014 | 58 528 | 0.0 | 30.2 | 6.7 | 36 925 | 0.0 | 0.0 | 36 921 | 100.0 | 20.8 | 0.3 | 0.1 |
| Swiss registries | 2000–2014 | 19 030 | 0.0 | 19.4 | 2.1 | 14 923 | 0.1 | 0.1 | 14 893 | 99.9 | 30.9 | 0.0 | 0.0 |
| UK | 2000–2014 | 227 965 | 0.1 | 22.9 | 4.8 | 163 761 | 0.2 | 0.0 | 163 337 | 98.5 | 30.8 | 4.3 | 0.0 |
| Oceania | 2000–2014 | 273 067 | 0.2 | 29.6 | 1.5 | 187 846 | 0.2 | 0.0 | 187 512 | 99.0 | 32.8 | 0.0 | 0.0 |
| Australia | 2000–2014 | 241 133 | 0.2 | 33.5 | 1.4 | 156 531 | 0.3 | 0.0 | 156 302 | 98.9 | 32.3 | 0.0 | 0.0 |
| New Zealand | 2000–2014 | 31 943 | 0.0 | 14.2 | 10.9 | 543 | 0.4 | 0.0 | 541 | 99.6 | 36.4 | 0.0 | 0.0 |
| Total | 2 303 095 | 0.4 | 27.7 | 3.5 | 1 586 551 | 0.5 | 0.0 | 1 578 482 | 99.2 | 43.2 | 2.5 | 1.6 |

DCO, death certificate only; MV, microscopically verified. *Other, records with incomplete data or for tumours that are benign (behaviour code 0), of uncertain behaviour (behaviour code 1), metastatic from another organ (behaviour code 6), or unknown if primary or metastatic (behaviour code 9); or for patients aged outside the range 15–99 years (adults); or with a topography code that is not in the range for skin (C440–C449), or the skin of the labia majora (C510), vulva (C519), penis (C609) or scrotum (C632). †Other, tumour coded with unknown vital status; or for patients for whom the sex is unknown. ‡Data with 100% coverage of the national population.
Fig 1 Morphology distribution by continent and country, all periods combined. NOS, not otherwise specified.
Malignant melanoma, not otherwise specified

Age-standardized 5-year net survival varied widely between world regions (Tables 1–3). It was in the range of 85–89% in Oceania and North America during 2010–2014. It was higher than 80% in all Western European countries and ranged from 54% to 79% in Eastern Europe. In Central and South America, age-standardized 5-year net survival ranged from 57% in Ecuador to 76% in Costa Rica and Puerto Rico. The 5-year survival was lower than 70% in all countries in the Asia region except Israel (88%), and was as low as 47% in Taiwan. The 5-year survival increased between 2000–2004 and 2010–2014 by 10% or more in China (from 36% to 48%), Bulgaria (from 52% to 62%), Croatia (from 66% to 77%) and Estonia (from 71% to 83%).

Superficial spreading melanoma

Age-standardized 5-year net survival for patients diagnosed during 2010–2014 was 90% or higher in North America, Oceania and almost all European countries; survival was lower than 90% in only Slovakia, Poland, Lithuania, Portugal and Bulgaria. In the Asia region, survival ranged from 71% in Taiwan to 98% in Israel (Figure 2).

Lentigo maligna melanoma

The lentigo maligna melanoma subtype had the most favourable prognosis; age-standardized 5-year net survival was close to 100% in North America, Australia and most European countries. Estimates were not available for most countries in Central and South America and Asia because of the small numbers of patients diagnosed with this specific subtype.

Nodular melanoma

The prognosis for nodular melanoma was the poorest in all continents. Age-standardized 5-year net survival for patients diagnosed during 2010–2014 reached 72% in Canada and the USA, 77% in New Zealand and 80% in Australia. In Central and South America, it ranged from 58% in Costa Rica to 72% in Argentina, and in Europe, it ranged from 58% in Poland to 80% in Ireland. Survival improved dramatically in Bulgaria (from 46% in 2000–2004 to 64% in 2010–2014) and in Portugal (from 59% to 76%).

Acral lentiginous melanoma

The 5-year net survival for adults diagnosed during 2010–2014 was in the range of 77–82% in North America and Oceania and 70–95% in Europe. Most of the estimates for countries in Asia and Central and South America were not age-standardized because of the small numbers of patients available for survival analysis. The 5-year net survival for adults diagnosed with desmoplastic melanoma during 2010–2014 ranged between 76% and 91%. Estimates were not available for Central and South America or for most countries in Asia because of the small numbers of patients available for analysis.

With the excess hazard of death for patients with superficial spreading melanoma taken as the reference category, the excess hazard ratio for patients diagnosed with nodular melanoma was 21.8 [95% confidence interval (CI) 14.7–32.3] in Germany, 12.1 (95% CI 8.1–18.1) in Spain and 6.7 (95% CI 5.7–7.9) in Norway (Table 5). The excess hazard ratios were lower after controlling for sex, age and stage at diagnosis, but the excess hazard of death for patients with nodular melanoma was still 13.5 (95% CI 9.6–18.9) times higher in Germany, 6.7 (95% CI 4.8–9.3) times higher in Spain and 4.1 (95% CI 3.6–4.8) times higher in Norway, than for patients in the same country diagnosed with superficial spreading melanoma.

The excess hazard ratio for patients diagnosed with acral lentiginous melanoma vs. superficial spreading melanoma was 15.2 (95% CI 9.0–25.5), 9.0 (95% CI 5.2–15.5) and 1.7 (95% CI 0.5–5.1) in Germany, Spain and Norway, respectively. After controlling for sex, age and stage at diagnosis, the excess hazard of death for patients with acral lentiginous melanoma was still 10.8-fold (95% CI 6.8–17.1) higher in Germany, fivefold (95% CI 3.1–8.1) higher in Spain and 2.2-fold (95% CI 1.0–4.9) higher in Norway, than for patients diagnosed with superficial spreading melanoma.

Discussion

This study of over 1.5 million adults diagnosed with cutaneous melanoma worldwide during 2000–2014 highlights wide international differences in the distribution of histological subtypes and differences in survival by subtype. For all countries investigated, the prognosis is poorest for nodular and acral lentiginous melanoma.

The prognostic role of the morphology of cutaneous melanomas is controversial. Clinical guidelines indicate that stage at diagnosis is the most important prognostic factor. The prevalent idea is that melanomas of different morphologies converge in their biological behaviour once they metastasize,29 so the recommended treatment options do not differ between morphological subtypes at a given stage at diagnosis. Furthermore, clinical guidelines indicate that the histological subtype is only an optional item for inclusion in pathology reports.30 This probably explains why the primary histological subtypes of melanoma are often poorly specified, if at all, in pathology reports.11,14 This in turn determines the high proportion of melanomas that are coded as ‘malignant melanoma, not otherwise specified (NOS)’ in cancer registry data.13 In this global study, 43% of melanomas were registered as malignant melanoma, NOS. The proportion varied widely, and was higher in Asia, Central and South America, and Eastern Europe, as has been shown elsewhere.13,31 However, our study demonstrates that the proportion of melanomas with poorly specified morphology has fallen in most countries over the last 15 years, which suggests that there have been improvements in pathological practice.32
Figure 2 Age-standardized 5-year net survival for patients diagnosed with cutaneous melanoma during 2010–2014 by continent, country and morphology group.

* Data with 100% coverage of the national population
Global variations in survival from cutaneous melanoma 2000–2014, V. Di Carlo et al.

Overall, superficial spreading melanoma was the most frequent of the specific morphologies, and the proportion of this morphological subtype has been increasing over time. This subtype is generally associated with an excellent prognosis in Europe, North America and Oceania, as has been shown in previous studies.\textsuperscript{13,14,29,33} Several international studies have shown an increasing incidence of thinner melanomas (1 mm or less)\textsuperscript{15,34–40} as a result of raised public awareness and earlier detection, especially for superficial spreading melanomas. The result is an increasing number of people with melanoma who are less likely to die as a result of their tumours. This phenomenon may help to explain the improvement in the already high 5-year net survival for superficial spreading melanoma.

Acral lentiginous melanoma accounted for less than 1% of the patients in Europe, North America and Oceania, but almost 6% of the patients in Asia and 7% in Central and South America. Very few studies have focused on survival from cutaneous melanoma in Africa.\textsuperscript{41} Perhaps because the overall incidence is much lower than in fairer-skinned populations. In Singapore, acral lentiginous melanoma accounted for 16% of all cases diagnosed during 2008–2017.\textsuperscript{41} In a study of 915 patients diagnosed with melanoma during 1997–2011 in Brazil, the acral subtype accounted for 7% of all cases and the 5-year cause-specific survival for this subtype was much lower (51%) than for superficial spreading melanoma (82%).\textsuperscript{42} A study of 142 patients in China confirmed the poor prognosis for patients with acral lentiginous melanoma; the 5-year cause-specific survival was 53%.\textsuperscript{43} By contrast, an analysis of 252 patients diagnosed in a single institution in Japan during 2001–2014 showed no difference between 5-year survival for acral and nonacral lentiginous subtypes (59% vs. 62% in men and 71% vs. 85% in women).\textsuperscript{44} However, the numbers of patients were too small to derive definitive conclusions.

Our study found that age-standardized 5-year net survival for acral lentiginous melanoma was generally lower than for other morphological subtypes, with the only exception of nodular melanoma, and was in the range of 66–95% globally. The poorer prognosis for acral lentiginous melanoma, which usually develops on the palms, the sole of the foot or underneath the nails, is commonly ascribed to delayed diagnosis because these areas are not routinely examined by patients or primary care physicians.\textsuperscript{45} Moreover, the proportion of the acral subtype is higher in black patients than in white patients;\textsuperscript{46} but because the risk of melanoma in black populations is perceived to be low, the lack of secondary prevention is also considered a major cause of late diagnosis.\textsuperscript{47,48} Nodular melanoma had the poorest prognosis in all countries, as has been reported elsewhere.\textsuperscript{49–51} In a study published over 40 years ago, a multivariable analysis of 339 patients diagnosed in a single institution in the USA during 1960–1977 found that the increased risk associated with nodular histology was confounded by an increase in thickness and ulceration; in other words, the higher risk of death was due to more advanced stage at diagnosis, and was not intrinsic to the morphological

| Country | Model 1 | EHR (95% CI) | n (%) | Model 2 | EHR (95% CI) | n (%) |
|---------|---------|-------------|-------|---------|-------------|-------|
| Germany (Lower Saxony) | | | | | | |
| Superficial spreading | 1.0 | 0.0–0.351 | 1.0 | 0.0–0.351 | 1.0 | 0.0–0.351 |
| Lentigo maligna | 0.1 | 0.0–0.175 | 0.1 | 0.0–0.175 | 0.1 | 0.0–0.175 |
| Nodular | 13.5 | 6.8–17.1 | 13.5 | 6.8–17.1 | 13.5 | 6.8–17.1 |
| Acral lentiginous melanoma | 10.8 | 5.8–15.5 | 10.8 | 5.8–15.5 | 10.8 | 5.8–15.5 |
| Malignant melanoma, NOS | 5.2 | 3.4–7.6 | 5.2 | 3.4–7.6 | 5.2 | 3.4–7.6 |
| Other morphologies | 3.4 | 2.6–4.9 | 3.4 | 2.6–4.9 | 3.4 | 2.6–4.9 |
| NOS, not otherwise specified (EHR, excess hazard ratio) | | | | | | |

Scottish registries, British Journal of Dermatology, 2017 (2000–2014).
On the basis of this conclusion from a small study, the American Joint Committee on Cancer did not include histological subtype in the cutaneous melanoma staging system because it was not considered to be a significant prognostic factor. However, 30 years later, a very large population-based study of 118,508 patients diagnosed in the USA with superficial spreading or nodular melanoma during 1973–2012 showed that morphology is in fact an independent predictor of survival. After controlling for thickness, ulceration, mitotic index and stage at diagnosis, nodular subtype remained an independent risk factor for death from melanoma (hazard ratio 1.55, 95% CI 1.41–1.70). Another population-based study of 82,901 patients diagnosed in Germany during 1997–2013 showed that differences in 5-year survival by histological subtype were “only” partially explained by tumour size.

Our population-based study confirms these findings. The multivariable analysis of data from four population-based registries with complete information on stage and morphology highlights a much higher excess risk of death for nodular or acral lentiginous melanoma than for superficial spreading melanoma, after controlling for major confounders. Sex, age and stage at diagnosis only partially explain the higher risk of death for nodular and acral lentiginous subtypes. The different magnitude of the excess hazard ratios in Germany, Spain and Norway may be due to the low baseline hazard for superficial spreading melanoma in Germany, where national skin cancer screening for people aged 35 years or more who have health insurance was introduced in 2008. This may have improved early detection of the generally slow-growing, less aggressive superficial spreading melanomas.

Our study has also shown that while 5-year survival from cutaneous melanoma in Eastern Europe has been increasing in recent years, survival continues to lag behind the rest of Europe for each morphological subtype of melanoma. A study of seven common malignancies diagnosed in Europe during 2000–2007 found that late stage at diagnosis alone did not explain the lower survival for melanoma of the skin in Eastern Europe. In the current study, data on stage at diagnosis in Eastern European countries were available only for Russia and Slovakia, where the proportion of metastatic disease (6% and 7%) was higher than in Norway (2%) and Denmark (3%) (data not shown). More detailed information on morphology would have helped in the investigation of the reasons for the persistent gap in survival.

The major limitation of our study was the high proportion of melanomas registered with poorly specified morphology, as this meant that the interpretation of net survival estimates for melanomas with specific morphological subtypes in all countries was limited. Information on stage at diagnosis was also limited; complete data could have contributed to the disentangling of the prognostic role of morphology at an international level. Additionally, we were not able to control for surgical margins, which are a relevant prognostic factor, as these data were not available.

Our study is the largest analysis to date of survival from cutaneous melanoma. It provides, for the first time, international comparisons of population-based survival for the main histological subtypes of melanoma from more than 50 countries. The higher frequency and poorer survival of nodular and acral lentiginous melanomas in Asia and in Central and South America suggest the need for health policies in these populations that are designed to improve public awareness, and especially to facilitate earlier diagnosis and prompt access to optimal treatment.

Funding sources
This project was supported by the American Cancer Society, Centers for Disease Control and Prevention, Swiss Re, Swiss Cancer Research Foundation, Swiss Cancer League, Institut National du Cancer, La Ligue Contre le Cancer, Rossy Family Foundation, The National Cancer Institute and the Susan G. Komen Foundation.

Conflicts of interest
The authors declare they have no conflicts of interest.

Data availability
These data are provided by more than 300 cancer registries worldwide. We hold the data in trust from each of the participating registries in order to perform the analyses agreed in the protocol. The protocol prohibits us from performing other analyses and from sharing the raw data with other parties, without express approval from the participating cancer registries.

Ethics statement
This study contains the results of secondary analysis of sensitive personal data, carried out with statutory approval from the Health Research Authority and ethical approval from the National Health Service Research Ethics Service.

References
1 van der Esch EP, Muir CS, Nectoux J et al. Temporal change in diagnostic criteria as a cause of the increase of malignant melanoma over time is unlikely. Int J Cancer 1991; 47: 483–90.
2 Coleman MP, Estève J, Damiecki P, Arslan A, Renard H. Trends in Cancer Incidence and Mortality. Lyon: International Agency for Research on Cancer, 1993.
3 Bray F, Colombet M, Mery L, Piñeros M, Znaor A et al. Cancer Incidence in Five Continents, vol. XI. Lyon: International Agency for Research on Cancer, 2017.
4 Chen YJ, Wu CY, Chen JT et al. Clinicopathologic analysis of malignant melanoma in Taiwan. J Am Acad Dermatol 1999; 41: 945–9.
5 Ishiihara K, Saida T, Otsuka F, Yamazaki N, The prognosis statistical investigation committee of the Japanese Skin Cancer Society. Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol 2008; 13: 33–41.
6 Allemani C, Matsuda T, Di Carlo V et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023–75.
Global variations in survival from cutaneous melanoma 2000–2014, V. Di Carlo et al. 379

7 Schoffer O, Schülein S, Arand G et al. Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011. BMC Cancer 2016; 16:936–48.

8 Rockberg J, Amelio JM, Taylor A et al. Epidemiology of cutaneous melanoma in Sweden. Stage-specific survival and rate of recurrence. Int J Cancer 2016; 139:2722–9.

9 Xing Y, Chang GJ, Hu CY et al. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer 2010; 116:2234–41.

10 Kemeny MM, Busch E, Stewart AK, Menck HR. Superior survival of young women with malignant melanoma. Am J Surg 1998; 175:437–44.

11 Galceran J, Uhry Z, Marcos-Gragera R et al. Trends in net survival from skin malignant melanoma in six European Latin countries: Results from the SUDCAN population-based study. Eur J Cancer Prev 2017; 26:577–584.

12 Emnina EAL, Moser JC, Weaver AL et al. Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011. Cimic Med 2017; 6:2203–12.

13 Crocetti E, Mallone S, Robsalm TE et al. Survival of patients with skin melanoma in Europe increases further: results of the EUROCARE-5 study. Eur J Cancer 2015; 51:2179–90.

14 Pollack LA, Li J, Berkowitz Z et al. Improved incidence and survival of cutaneous melanoma in the United States, 1992 to 2005. J Am Acad Dermatol 2011; 65:578–86.

15 Downing A, Yu XQ, Newton-Bishop J, Forman D. Trends in prognostic factors and survival from cutaneous melanoma in Yorkshire, UK and New South Wales, Australia between 1993 and 2003. Int J Cancer 2008; 123:861–6.

16 Clark WH Jr, From J, Bernardino EA, Mihm MC. The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res 1969; 29:705–26.

17 Elder DE, Massi D, Scolyer RA, Willemze R. Further development of flexible parametric models for survival analysis. Ann Surg Oncol 2017; 24:441–50.

18 Ackerman AB, David KM. A unifying concept of malignant melanoma: biologic aspects. Hum Pathol 1986; 17:438–40.

19 Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L et al. International Classification of Diseases for Oncology, first revision of 3rd edn. Geneva: World Health Organization, 2013.

20 Pohar Perme M, Stare J, Estève J. On estimation in relative survival. Biostatistics 2012; 68:113–20.

21 Clerc-Urmès I, Gréchy M, Hedelin G. Net survival estimation with stns. Stat J 2014; 14:87–102.

22 Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer 1996; 78:2004–10.

23 Corazzari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004; 40:2307–16.

24 United Nations Statistics Division. Methodology: standard countries or area codes for statistical use (M49). Available at: https://unstats.un.org/unsd/methodology/m49/ (last accessed 11 February 2022).

25 Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stat J 2009; 9:165–90.

26 Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17:1471–4.

27 Berrino F, Brown M, Moller C, Sobin L. ENCR recommendation: Condensed TNM for Coding the Extent of Disease. Lyon: European Network of Cancer Registries, 2002.

28 Young JL, Roffers SD, Ries LAG et al. SEER Summary Staging Manual 2000: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute, 2001.
50 Shaikh WR, Xiong M, Weinstock MA. The contribution of nodular subtype to melanoma mortality in the United States, 1978 to 2007. Arch Dermatol 2012; 148:30–6.

51 Mar V, Roberts H, Wolfe R et al. Nodular melanoma: a distinct clinical entity and the largest contributor to melanoma deaths in Victoria, Australia. J Am Acad Dermatol 2013; 68:568–75.

52 Balch CM, Murad TM, Soong SJ et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark’s and Breslow’s staging methods. Ann Surg 1978; 188:732–42.

53 Balch CM, Buzaid AC, Soong SJ et al. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol 2003; 21:43–52.

54 Brunssen A, Jansen L, Eisemann N et al. A population-based registry study on relative survival from melanoma in Germany stratified by tumor thickness for each histologic subtype. J Am Acad Dermatol 2019; 80:938–46.

55 Minicozzi P, Walsh PM, Sánchez M-J et al. Is low survival for cancer in Eastern Europe due principally to late stage at diagnosis? Eur J Cancer 2018; 93:127–37.

**Supporting Information**

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

**Appendix S1** CONCORD Working Group.

**Table S1** Malignant melanoma of the skin: distribution by morphology group, country and calendar period of diagnosis.